FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
March 14, 2024 17:18 ET
|
Global Liver Institute
Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...
Patient-Focused Next Generation Home Blood Test for Cardiometabolic Health Now Available to Consumers
August 28, 2023 12:08 ET
|
CardioMetaboliQ LLC
—An alarming 93 percent of US adults have less than optimal cardiometabolic health1 and many are completely unaware of their risk— —New test provides end-to-end cardiometabolic health solution, with...
A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH
July 18, 2023 09:29 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 18, 2023 (GLOBE NEWSWIRE) -- Data from the Centers for Disease Control & Prevention (CDC) suggests just over seventy percent of American adults are overweight,...
Fatty Liver Diseases Treatment Market to Exhibit an Incredible Growth of USD 28 Billion by 2030, Size, Share, Trends, Key Drivers, Demand and Opportunity Analysis
April 18, 2023 12:30 ET
|
Data Bridge Market Research
Philadelphia, April 18, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research completed a qualitative study titled "Fatty Liver Diseases Treatment Market" with 100+ market data tables, pie charts,...
Inventiva annonce la présentation de trois abstracts scientifiques lors de l’EASL International Liver Congress™ 2022
June 09, 2022 16:00 ET
|
INVENTIVA
Trois présentations par poster démontrant : les effets bénéfiques de lanifibranor sur les marqueurs de la santé cardiométabolique chez les patients atteints de NASH avec fibrose non cirrhotique,...
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
June 09, 2022 16:00 ET
|
INVENTIVA
Three poster presentations showing the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.the...